TLR9

InDex Pharmaceuticals gets new patent for cobitolimod granted in the US

Retrieved on: 
Tuesday, November 9, 2021
IIB, TLR9, Safety, Ulcerative colitis, DIMS, The Lancet, Index, Certification, Hepatology, DNA, Patent, Nasdaq, EU, MAR, Pharmaceutical industry

This information is information that InDex Pharmaceuticals Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (MAR).

Key Points: 
  • This information is information that InDex Pharmaceuticals Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (MAR).
  • The information was submitted for publication through the agency of the contact person set out above at 12:25 CET on November 9, 2021.
  • Cobitolimod met the primary endpoint in the phase IIb study CONDUCT and demonstrated an outstanding combination of efficacy and safety.
  • InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options.

Statera Biopharma Honors Pancreatic Cancer Awareness Month

Retrieved on: 
Monday, November 1, 2021
Lung, Pancreatic cancer, Cancer, American Cancer Society, Foundation, Research, Regulation of tobacco by the U.S. Food and Drug Administration, Budget, Disease, European Union, Awareness, TLR, Organization, Patient, Virus, FDA, Hematology, Fibromyalgia, TLR4, Cleveland BioLabs, Food, TLR5, Multiple sclerosis, Antibody, SEC, Exercise, TLR9, Homeostasis, Annual report, Risk, Company, CEO, COVID-19, Growth, Type, Union, Lung cancer, Nasdaq, Entolimod, Autoimmunity, Population, GLOBE, Cleveland, Colon, Coronavirus, Pharmaceutical industry

FORT COLLINS, Colo., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced its support forPancreatic Cancer Awareness Month, designated as the month of November.

Key Points: 
  • FORT COLLINS, Colo., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced its support forPancreatic Cancer Awareness Month, designated as the month of November.
  • Michael K. Handley, President and CEO of Statera Biopharma, stated, Pancreatic cancer remains a devastating disease despite the tremendous advances in cancer research.
  • The American Cancer Society predicts that it could become the second-leading cause of cancer-related death behind lung cancer.
  • Statera has clinical or preclinical programs for Crohns disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to potential expansion into fibromyalgia and multiple sclerosis.

Checkmate Pharmaceuticals Announces Final Data Presentation for Phase 1b Study Evaluating Vidutolimod at The Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Retrieved on: 
Monday, November 1, 2021
Financial condition report, U.S. Securities and Exchange Commission, Securities Act of 1933, CpG, LinkedIn, CMPI, Society for Immunotherapy of Cancer, Immunotherapy, Twitter, File, Analysis, Security (finance), NASDAQ, Private Securities Litigation Reform Act, Society, Result, TLR9, Review, Social media, Annual report, Forward-looking statement, COVID-19, Checkmate, Immune system, GLOBE, SITC, Pharmaceutical industry

Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer.

Key Points: 
  • Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer.
  • Information regarding Checkmate Pharmaceuticals is available at www.checkmatepharma.com .
  • The information that Checkmate Pharmaceuticals posts on these channels and websites could be deemed to be material information.
  • All information in this press release is as of the date of the release, and Checkmate undertakes no duty to update this information unless required by law.

Checkmate Pharmaceuticals Announces CEO Transition

Retrieved on: 
Wednesday, October 27, 2021
Financial condition report, Melanoma, Eli Lilly, U.S. Securities and Exchange Commission, Biotechnology, CpG, LinkedIn, CFO, Securities Act of 1933, Â, Twitter, File, Analysis, Sustainability Accounting Standards Board, Security (finance), Private Securities Litigation Reform Act, Result, Audit committee, TLR9, Agriculture, PricewaterhouseCoopers, SEC, Business administration, AbbVie, Agricultural economics, Review, Montana State University, Social media, Daiichi Sankyo, Annual report, Forward-looking statement, Company, CEO, Board, COVID-19, Growth, Esperies, Nasdaq, Immune system, Therapy, MicroRNA, GLOBE, Cooper, Sale, Esperion Therapeutics, Pharmaceutical industry

CAMBRIDGE, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (Checkmate), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Alan Fuhrman has been appointed as interim President and CEO.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (Checkmate), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Alan Fuhrman has been appointed as interim President and CEO.
  • Mr. Fuhrman succeeds Barry Labinger, who has transitioned from his roles as President and CEO and Director.
  • Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer.
  • The information that Checkmate Pharmaceuticals posts on these channels and websites could be deemed to be material information.

Checkmate Pharmaceuticals Announces Webcast on Innate Immune Modulators and Vidutolimod (CMP-001)

Retrieved on: 
Wednesday, October 20, 2021
Head, Financial condition report, Melanoma, U.S. Securities and Exchange Commission, Securities Act of 1933, CpG, LinkedIn, Cancer, Merkel-cell carcinoma, Drug development, Twitter, File, Analysis, Security (finance), Patient, Founder, Investor, Private Securities Litigation Reform Act, Result, TLR9, Review, Jefferies, Social media, Annual report, Forward-looking statement, Webcast, COVID-19, Checkmate, FACP, Nasdaq, Justice and Security Act 2013, Research, Immune system, Q&A, GLOBE, Vaccine, Pharmaceutical industry

CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced a live webcast on innate immune modulators and vidutolimod (CMP-001) hosted by Jefferies on Tuesday, October 26 from 11:00am – 12:00pm ET.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (Checkmate), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced a live webcast on innate immune modulators and vidutolimod (CMP-001) hosted by Jefferies on Tuesday, October 26 from 11:00am 12:00pm ET.
  • in a scientific discussion of the role of innate immune modulators in cancer treatment.
  • An archived copy of the webcast will be available on the Checkmate website for approximately 90 days after the event.
  • Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer.

Statera Biopharma, Inc. Announces Institutional Review Board Approves Study of STAT-205 for Acute COVID-19

Retrieved on: 
Tuesday, October 19, 2021
Linda, Biomarker, Virus, Multiple sclerosis, Risk, Pharmacokinetics, Degenerative disease, Cancer, Cleveland, COVID-19, Antibody, Autoimmunity, European Union, TLR4, Growth, Pancreatic cancer, TLR, Institutional review board, Coronavirus, Annual report, Severe acute respiratory syndrome coronavirus 2, Disease, Fibromyalgia, Exercise, Safety, Research, TLR5, Cleveland BioLabs, Nasdaq, IRB, Entolimod, CEO, HIV disease progression rates, GLOBE, Patient, Delta, Homeostasis, PACS, Union, SEC, TLR9, Budget, Company, Vaccine, Pharmaceutical industry

FORT COLLINS, Colo., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that it has received Institutional Review Board (IRB) approval to conduct a Phase 1 pilot study at Loma Linda University Health to evaluate STAT-205 as a treatment to mitigate SARS-CoV-2 progression, the virus that causes COVID-19. STAT-205 is an immune-modulator designed to decrease elevated inflammatory responses associated with viral infection and inhibit viral replication in human lung cells.

Key Points: 
  • STAT-205 is an immune-modulator designed to decrease elevated inflammatory responses associated with viral infection and inhibit viral replication in human lung cells.
  • During preclinical in vitro studies, STAT-205 demonstrated an ability to inhibit the replication of coronaviruses in human lung cells.
  • Statera is also developing STAT-205 as a treatment for patients with post-acute COVID-19 syndrome (PACS), also known as long haulers.
  • Approximately 30% of patients with acute COVID-19 develop long haul syndrome, and these patients also represent a significant unmet medical need.

Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders

Retrieved on: 
Friday, October 8, 2021
Gene silencing, Twitter, Tumor microenvironment, Forward-looking statement, Annual Meetings of the International Monetary Fund and the World Bank Group, Proxy, Delaware Court, Sirna, GLOBE, Therapure BioPharma Inc, U.S. Securities and Exchange Commission, Sutro Biopharma, Delaware, Communication, TLR9, Immunotherapy, TLR, RNA, Acquisition, Delaware Court of Chancery, Nasdaq, Annual general meeting

The adjourned meeting will be held by means of remote communication and can be accessed via the following URL: http://www.cesonlineservices.com/scps21_vm .

Key Points: 
  • The adjourned meeting will be held by means of remote communication and can be accessed via the following URL: http://www.cesonlineservices.com/scps21_vm .
  • The record date for the Annual Meeting will remain August 16, 2021.
  • Scopus continues to solicit votes from its stockholders with respect to the proposals set forth in Scopus proxy statement dated September 16, 2021.
  • Proxies previously submitted in respect of the Annual Meeting will be voted at the adjourned Annual Meeting unless properly revoked, and stockholders who have previously submitted a proxy or otherwise voted and who do not want to change their vote need not take any action.

Statera Biopharma, Inc. to Participate in the A.G.P. Biotech and Specialty Pharma Conference

Retrieved on: 
Wednesday, October 6, 2021
Cancer, Exercise, Pancreatic cancer, Risk, Cleveland, Entolimod, Annual report, Conference, Patient, Homeostasis, Virus, TLR5, TLR9, GLOBE, TLR, TLR4, Cleveland BioLabs, Company, Antibody, European Union, Coronavirus, Growth, Autoimmunity, COVID-19, Union, Research, Nasdaq, Multiple sclerosis, SEC, Fibromyalgia, Budget, Pharmaceutical industry

Biotech and Specialty Pharma Conference taking place October 13, 2021.

Key Points: 
  • Biotech and Specialty Pharma Conference taking place October 13, 2021.
  • Michael K. Handley, President and Chief Executive Officer of Statera, and other members of the Statera management team will be available for one-on-one meetings with registered conference attendees.
  • The company announced its new corporate name, Statera Biopharma, on August 31, 2021.
  • The forward-looking statements included in this press release are made only as of the date hereof.

TriSalus Life Sciences Appoints Industry Expert Sean Murphy to Board of Directors

Retrieved on: 
Tuesday, October 5, 2021
Biotechnology, Pharmaceutical, Health, Neoplasm, Artificial intelligence, Pressure, Immunosuppression, Solution, Therapy, Board of directors, Western Illinois University, Cancer, List of life sciences, Patient, Health, Region, LinkedIn, Board, Evercore, Immune system, TLR9, Immunotherapy, Twitter, Medicine, University, Abbott, Program, Knowledge, Growth, UV, Disease, Trial of the century, Liver, Drug, CAR, Fortune 500, Blood, Industry, Champaign County, Illinois, Pharmaceutical industry, Medical imaging

TriSalus Life Sciences , an interventional immunotherapy company on a mission to improve the lives of patients living with liver and pancreatic cancers by dramatically transforming the way these devastating diseases are treated, today announced the appointment of Sean Murphy to its Board of Directors.

Key Points: 
  • TriSalus Life Sciences , an interventional immunotherapy company on a mission to improve the lives of patients living with liver and pancreatic cancers by dramatically transforming the way these devastating diseases are treated, today announced the appointment of Sean Murphy to its Board of Directors.
  • Most recently, Murphy served as the executive vice president of Malin PLC, a company he co-founded, where he led oversight of a large portfolio of highly innovative life sciences companies.
  • We are excited to have Sean, an industry titan with decades of experience, join the Board of TriSalus Life Sciences.
  • Its an honor to be appointed to the TriSalus Board of Directors and leverage my industry experience to help make a positive change in the lives of patients dealing with such hard-to-treat cancers, said Sean Murphy.

Statera Biopharma Announces CEO Mike Handley to Speak During Virtual B & T Cell-Mediated Autoimmune Disease Drug Development Summit

Retrieved on: 
Tuesday, October 5, 2021
Cancer, Exercise, Pancreatic cancer, Risk, Cleveland, Entolimod, Annual report, Patient, Investor relations, Virus, Homeostasis, TLR5, TLR9, TLR, TLR4, Cleveland BioLabs, Hematology, Company, Antibody, European Union, Growth, Lymphocyte, Autoimmunity, Coronavirus, Autoimmune disease, COVID-19, Union, Research, B cell, Multiple sclerosis, SEC, Fibromyalgia, Budget, Vaccine

Stateras internal pipeline includes clinical-stage programs for Crohns disease, COVID-19, pancreatic cancer and hematology.

Key Points: 
  • Stateras internal pipeline includes clinical-stage programs for Crohns disease, COVID-19, pancreatic cancer and hematology.
  • Mr. Handleys presentation will be available for viewing by all registered conference attendees on the summits virtual platform.
  • A recording of event will be available in the Investor Relations section of the Statera website following the conclusion of the conference.
  • Statera has clinicalprograms for Crohns disease (STAT-201),hematology (Entolimod), pancreatic cancer (STAT-401) andCOVID-19 (STAT-205) in addition to expansion into fibromyalgia and multiple sclerosis.To learn more about Statera Biopharma, please visit www.staterabiopharma.com.